Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products
Vaxxas, a clinical-stage biotech company commercializing new vaccine platform technology, today announced the opening of its first state-of-the-art manufacturing facility in Brisbane, Queensland. The purpose-built 5,500-square-foot (60,000 square foot) Vaxxas Biomedical Facility will serve as the company’s global headquarters and…